$362.08+48.69% · 3M
Moving avg
1W+4.09%
1M+21.67%
3M+48.69%
6M+23.29%
YTD+18.61%
1Y+31.78%
3Y-8.36%
5Y-52.76%
52-week range
$236.73100% of range$343.12
Company health
Value2/6
Growth4/6
Profitability6/6
Health5/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- Strong 29% net margin
- High return on equity (240%)
Risks
- Richly valued at 51.3x earnings
- Trades 11% above the average analyst target
Key statistics
Valuation
Market cap
$9.75B
Enterprise value
$9.34B
P/E ratio (TTM)
51.27x
P/S ratio (TTM)
3.27x
EV/EBITDA
19.89x
Per share & returns
EPS (TTM)
$6.26
Dividend yield
0.00%
Beta (1Y)
1.08
30-day change
+21.67%
Trading
Volume (24h)
186.59K
Previous close
$356.25
Shares outstanding
26.92M
About Bio-Rad Laboratories, Inc.
Sector
Healthcare
Industry
Medical - Devices
Exchange
NYSE
Symbol
BIO
Bio-Rad Laboratories, Inc. is a mid-cap healthcare company in the Medical - Devices industry. Its shares are listed on NYSE (United States) and trade under the ticker BIO.
Frequently asked questions
What is Bio-Rad Laboratories, Inc.'s market cap?
Bio-Rad Laboratories, Inc. (BIO) has a market capitalization of $9.75B.
What is Bio-Rad Laboratories, Inc.'s P/E ratio?
Bio-Rad Laboratories, Inc. trades at a price-to-earnings (P/E) ratio of 51.27.
What exchange does BIO trade on?
BIO trades on NYSE.
Appears in
Eli Lilly and CompanyLLY
$1,220.51+0.45%
$1.15T cap
Johnson & JohnsonJNJ
$260.86+0.41%
$628.65B cap
AbbVie Inc.ABBV
$248.66-0.57%
$439.33B cap
UnitedHealth Group IncorporatedUNH
$405.59+0.85%
$368.33B cap
Roche Holding AGSWX: ROP
CHF 364.50-0.27%
$356.95B cap
Merck & Co., Inc.MRK
$132.93+1.92%
$328.31B cap
Novartis AGSWX: NOVN
CHF 123.92-0.23%
$289.77B cap
AstraZeneca PLCLON: AZN
£116.20-0.70%
$242.95B cap